Radio Nuclide Therapy: From Molecular to Cure
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2373
Special Issue Editor
Interests: molecular imaging; radiopharmacology; bone metastases therapy; amyloidosis; intraoperative detection
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
After the introduction of radioiodine therapy for thyrotoxicosis and differentiated thyroid cancer in the middle of the last century, radionuclide therapy (RNT) underwent an enormous development exploring innovative ways.
Despite this, RNT faces many challenges and limitations:
- A molecular vector with high affinity and specificity for the tumor target;
- A nuclide, preferable a true theranostic, with the emission and effective half-life fitting with uptake rate and residence in the target;
- The chelator and cages;
- Nanogenerators;
- Tumor cells kinetics and metabolism;
- Cell radiobiology;
- Combined use with chemotherapeutics, biological drugs and EBRT, beta and alpha sequence.
We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.
Dr. Carlo Aprile
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alpha emission
- beta emission
- radiobiology
- cancer therapy
- radiopharmaceutical
- internal radiotherapy
- radionuclides
- theranostic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
